Chris Tyler

Chris Tyler

Chris Tyler, a Wall Street veteran of more than 20 years, began his career in the financial markets working on the trading floor of the AMEX in New York as an equity option market maker at Interactive Brokers’ floor trading unit Timber Hill LLC.

After moving to San Francisco to make markets on the P-Coast exchange during the dot-com craze and spending nearly a decade working in names like Philip Morris, Seagate and Compaq, Chris hung up his smock and trading badge, but not his passion for options and the markets.

Since exiting the floor, and for the better part of the past dozen years, Chris has worked as an option and market strategist, writing analyses for Trading Markets, Charles Schwab subsidiary Optionetics and as a featured columnist at Investor’s Business Daily.

Aside from offering his trading insights at InvestorPlace.com, Chris is currently studying for his Accredited Portfolio Management Advisor (APMA) designation, manages investments for closely held accounts and offers his services as an investment strategist to GLJ Advisors, a CA based RIA.

Chris, his wife and blue heeler live in the Pacific NW. And if you can’t follow him around in your own VW Vanagon or Westfalia, feel free to follow him on Twitter via @Options_CAT.

Recent Articles

3 Very Buyable, Doggish Dow Jones Stocks to Buy

Think the market has gotten ahead of itself? Well, think again by taking another look at these three Dow Jones stocks to buy.

Plug Power Stock Offers Serious Momentum

Plug Power has been thriving thanks to growing interest in the EV market. Here's how PLUG stock stands to benefit.

Here’s How SOLO Stock Can Add Torque to Your Portfolio

The latest EV stock to make a splash with investors may not wind up being the greatest, but SOLO stock has a lot working in its favor now.

Is Genius Brands Stock Finally a Smart Purchase?

Don’t expect the next Netflix, but a purchase of GNUS stock is looking timely enough based on what’s happening and what’s possible both off and on the price chart

Why It’s Not Too Late to Buy SRNE Stock

The world wants a Covid-19 vaccine, but for biotech investors eyeing Sorrento for additional upside potential, there’s a better therapy for risk-adjusted returns in the options market